• Explore /
  • Poster
  • / Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

Abstract Poster

Authors

null

Jacqueline Vuky

Oregon Health & Science University, Portland, OR

Jacqueline Vuky , Arjun Vasant Balar , Daniel E. Castellano , Peter H. O'Donnell , Petros Grivas , Joaquim Bellmunt , Thomas Powles , Dean F. Bajorin , Noah M. Hahn , Ronald De Wit , Mary Savage , Lei Pang , Tara L. Frenkl , Stephen Michael Keefe , Elizabeth R. Plimack

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02335424

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4524)

DOI

10.1200/JCO.2018.36.15_suppl.4524

Abstract #

4524

Poster Bd #

350

Abstract Disclosures

Similar Posters

First Author: Peter H. O'Donnell

First Author: Matt D. Galsky

First Author: Arjun Vasant Balar

Poster

2024 ASCO Gastrointestinal Cancers Symposium

First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.

First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.

First Author: Kunihiro Fushiki